Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Unlocking Global Gaming Potential for Brands
    Unlocking Global Gaming Potential for Brands World News
  • Penetration Testing Software Market to Outstrip $ 4,045.2Mn by 2028 Growing Sturdy at 14.4% CAGR
    Penetration Testing Software Market to Outstrip $ 4,045.2Mn by 2028 Growing Sturdy at 14.4% CAGR World News
  • Convenience over Validation in Furniture ECommerce: ECommerce specialists YRC explains
    Convenience over Validation in Furniture ECommerce: ECommerce specialists YRC explains Business
  • New GGI Website Showcases the Versatility of Architectural Glass
    New GGI Website Showcases the Versatility of Architectural Glass Business
  • War Day 152: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 152: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • SimplyRFiD Launches Same-Day SGTIN RFID Encoding Service for Retail
    SimplyRFiD Launches Same-Day SGTIN RFID Encoding Service for Retail Business
  • Industrial Metal Supply Opens Seventh Store in San Jose
    Industrial Metal Supply Opens Seventh Store in San Jose Business
  • Anila Ali, Pakistani American Advocate Appointed G100 Anti- Gender Based Violence Chair for Pakistan
    Anila Ali, Pakistani American Advocate Appointed G100 Anti- Gender Based Violence Chair for Pakistan World News
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Posted on October 24, 2022 By NewsEditor
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
GB Sciences


LAS VEGAS - October 24, 2022 - (Newswire.com)

Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company's first non-cannabis formulations to advance in preclinical studies.

"We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations," said Dr. Andrea Small-Howard, Gb Sciences' President and Chief Science Officer. "This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs."

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

[email protected]


Contact Information:
Madeleine Moench
[email protected]


Press Release Service by Newswire.com

Original Source: Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
Business

Post navigation

Previous Post: Genomes Partners With CariGenetics to Launch a Decentralized Lab for Breast Cancer Research
Next Post: NREP Launched New Emergency Planning Professional Certification

Related Posts

  • Digital PCR Market Size (USD 1.30 billion by 2030): Precision Diagnostics and Personalized Healthcare at the Forefront
    Digital PCR Market Size (USD 1.30 billion by 2030): Precision Diagnostics and Personalized Healthcare at the Forefront Business
  • Celebrating Sustainable Practices for Earth Day With Vistatec
    Celebrating Sustainable Practices for Earth Day With Vistatec Business
  • Project11 Limited Announces Licensing Agreement with P11 EMEA Limited
    Project11 Limited Announces Licensing Agreement with P11 EMEA Limited Business
  • Forensic Payroll Consultants, Inc. (FPC) Announce Comprehensive Employment Tax Solutions for Employers Involved in Acquisitions
    Forensic Payroll Consultants, Inc. (FPC) Announce Comprehensive Employment Tax Solutions for Employers Involved in Acquisitions Business
  • ICA Offers Live Classes in Arkansas for Home Inspector Continuing Education
    ICA Offers Live Classes in Arkansas for Home Inspector Continuing Education Business
  • Tru Treasury and ZSuite Tech Announce Strategic Collaboration, Launching Innovative Escrow Tool for Credit Unions
    Tru Treasury and ZSuite Tech Announce Strategic Collaboration, Launching Innovative Escrow Tool for Credit Unions Business
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« May    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Trends, Growth, and Insights Through 2034June 3, 2025
  • Payroll Service Companies Drive Efficiency and Compliance for Texas SMBsJune 3, 2025
  • Forward Edge-AI wins patent for blockchain-secure, quantum-proof ML updates—a leap for trusted AI governance.June 2, 2025
  • Mainstreaming Women’s Health in Congress with the First-Ever Women’s Health Capitol Hill DayJune 2, 2025
  • Electronic Nose Market Set To Reach $52.32 Billion By 2029, At A CAGR Of 14.1%June 2, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Office of Art in Embassies Celebrates 60 Years with Art Diplomacy for Democracy
    Office of Art in Embassies Celebrates 60 Years with Art Diplomacy for Democracy World News
  • The Social Benefits of Sustainable Agriculture
    The Social Benefits of Sustainable Agriculture Business
  • Lost Oak Winery Partners with Critically Acclaimed Consulting Winemaker Jean Hoefliger
    Lost Oak Winery Partners with Critically Acclaimed Consulting Winemaker Jean Hoefliger Business
  • Kaishan USA Launches New Industrial Vacuum Pump
    Kaishan USA Launches New Industrial Vacuum Pump Business
  • Condolences on Helicopter Crash in Ukraine
    Condolences on Helicopter Crash in Ukraine World News
  • KogoPAY Champions Fintech’s Role in Climate Action at Green Technology Expo
    KogoPAY Champions Fintech’s Role in Climate Action at Green Technology Expo Business
  • U.S. Department of State Concludes ,000,000 Settlement of Alleged Export Violations by 3D Systems Corporation
    U.S. Department of State Concludes $20,000,000 Settlement of Alleged Export Violations by 3D Systems Corporation World News
  • Maryam Rajavi Welcomes Bipartisan Iranian Women Caucus and Resolution Condemning Iran Regime’s Poisoning of School Girls
    Maryam Rajavi Welcomes Bipartisan Iranian Women Caucus and Resolution Condemning Iran Regime’s Poisoning of School Girls World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .